Business / Finance

RSS

Patient Safety Technologies fourth quarter total revenues decrease to $2.7M

Patient Safety Technologies, Inc. today announced results for its fourth quarter and fiscal year 2011 ended December 31st, 2011.

26 Mar 2012

OncoSec to purchase $7.75M of securities in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase $7.75 million of securities in a registered public offering.

26 Mar 2012

Asahi Kasei announces commencement of tender offer for ZOLL

Asahi Kasei Corporation, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the commencement of a tender offer through its indirect wholly owned U.S. subsidiary Asclepius Subsidiary Corporation for all outstanding shares of common stock of ZOLL Medical Corporation for $93 per share, net to the seller in cash, without interest and less any required withholding taxes.

26 Mar 2012

BiO2 Medical completes $13.7M Series B round of funding

BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently completed its $13.7M Series B round of funding, which included the conversion of a $1M State of Texas Emerging Technology Fund (ETF) award.

26 Mar 2012

Islet Sciences acquires DTI

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the closing of the acquisition of DiaKine Therapeutics, Inc., a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes which is now the Company's wholly owned subsidiary.

26 Mar 2012

ImpactRx announces acquisition of AlphaDetail

ImpactRx, a Symphony Technology Group (STG) company, and the pioneer in measuring the impact of promotion on physicians' attitudes and prescribing behavior, announced today that it has acquired AlphaDetail, Inc., a leader in global healthcare primary market research and influence network mapping.

26 Mar 2012

Quest Diagnostics unveils redesigned corporate website

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, has unveiled its redesigned corporate website at www.QuestDiagnostics.com.

From Quest Diagnostics 23 Mar 2012

Hyperion acquires worldwide rights to Ucyclyd's Ravicti

Hyperion Therapeutics, Inc. today announced that it has acquired worldwide rights to the investigational drug Ravicti from Ucyclyd Pharma, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation.

23 Mar 2012

FMBFarma granted exclusive rights to market Ampio's Zertane for PE in Brazil

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, and FBM Industria Farmaceutica Ltda, a member of the HOSPFAR Group that manufactures, imports and distributes pharmaceuticals in Brazil, today announced a license and distribution agreement providing FMBFarma exclusive rights to market Zertane in Brazil for the treatment of premature ejaculation.

22 Mar 2012

Schiff third quarter net sales increase 25% to $72.2 million

Schiff Nutrition International, Inc., announced results for the three- and nine-month periods ended February 29, 2012.

22 Mar 2012

Roundup: States face new revenue downturn; Calif. county has disparities in life expectancy

Revenues in most U.S. states increased in the fourth quarter of 2011, but their recent surge is tapering off, as they grew just 2.7 percent from the final quarter of 2010, according to a report released on Monday. "This is a noticeable slowdown from the 11.1 (percent) and 6.1 percent year-over-year growth reported in the second and third quarters of 2011, respectively," the Rockefeller Institute, a think tank that closely watches states' revenues, said in the report.

21 Mar 2012

MDOL announces acquisition of MD Technologies

MD On-Line, Inc. (MDOL), a leading provider of electronic healthcare solutions that leverage data to improve practice efficiency and industry connectivity, announced today that it has acquired MD Technologies Inc., a healthcare technology company based in Baton Rouge, Louisiana.

21 Mar 2012

MSN completes sale of HomeCare division to Epic

Medical Staffing Network Healthcare, LLC, one of the nation's largest healthcare workforce solutions companies, today announced it has completed the sale of its MSN HomeCare division to Epic Health Services of Dallas, Texas.

21 Mar 2012

Universal to acquire Seitz ProShield assets

Universal Capital Management, Inc. announced today a non-binding letter of intent to purchase ProShield assets, a product owned by Seitz Technical Products, Inc.

21 Mar 2012

FPS acquires Psych Support

Family Preservation Services (FPS) of North Carolina, Inc., a leading provider of mental health services for at-risk and disadvantaged youth and adults with severe and persistent mental illness, today announced it has acquired substantially all of the assets of Psych Support Inc., a Raleigh-based Critical Access Behavioral Health Agency.

21 Mar 2012

Thermedical closes $1.5 million in Series A funding

Thermedical, a privately held company developing proprietary thermal therapy equipment for numerous clinical conditions, today announced that it closed $1.5 million in Series A funding with a private investor, Samuel H. Maslak, Sc.D.

21 Mar 2012

GeoVax enters into definitive agreements to sell Series A convertible preferred stock

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common stock with an exercise price of $1.00 per share and a term of five years.

21 Mar 2012